'Sunshine' hits Europe: Pharma's doc payments now available, but numbers are far from comprehensive

Photo courtesy of NutritionFacts.org.

The sun is finally shining on drug company payments to doctors in Europe. Under the disclosure requirement by the European Federation of Pharmaceutical Industries and Associations (EFPIA), U.K. drugmakers officially reported numbers for 2015 on June 30 and payment information across the association's 33-country coverage area has begun to trickle out.

And "trickle" is the operative word--because compliance in most EU countries is voluntary, the tallies are far from complete. And in the U.K., many doctors aren't allowing their numbers to see the light of day.

In the U.K., more than £340 million worth of payments were made to doctors in 2015, according to the Association of the British Pharmaceutical Industry's (ABPI) new searchable database. Dubbed Disclosure U.K., the database is similar to the United States' Open Payments Database, and it allows the public to search by doctor or company for specific non-research payments and benefits, according to the Financial Times.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

France, Denmark and Portugal are the only European countries where compliance is not voluntary and the U.K. association estimates that only about 70% of healthcare professionals identified by pharma and biotech companies have agreed to participate, the FT reported. Those who are reporting only make up about half of all payment value, meaning some of the highest-paid recipients are likely not disclosing, the head of the group told FT.

Meanwhile, the Ireland Pharmaceutical Association defended its pharma members' payment of €27 million, telling RTE that the transfers of value are mostly related to research and development, event expenses, and donations, grants or fees for services and consulting.

Compliance is an issue in Ireland as well, RTE reported, with only 45% of doctors and healthcare professionals agreeing to have their names published in its "transfer of value" database.

The U.S. Open Payments Database also recently updated its payments for 2015 to doctors on June 30, reporting $7.52 billion total spent by pharma, up just slightly from the 2014 total of $7.49 billion.

- see the FT's coverage (sub. req.)
- read the RTE news

Special Report: Top 10 drug brands by payments to doctors

Related Articles:
Drugmakers to open their doc-payment books in Europe
Pharma's doctor payments do pay off, with more money yielding more scripts: ProPublica
Does free food really sway docs toward brands? Think data and samples instead, sales expert says

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.